Melanoma Clinical Trial
Study of the Nevisense Device to Assess Atypical Skin Lesions
Summary
The purpose of this study is to find out whether the Nevisense device can provide useful information about atypical moles to complement the usual assessments done during routine screening for melanoma. Assessing particpants' moles with the Nevisense device may help improve screening methods for the early detection of melanoma in people with atypical mole syndrome.
Eligibility Criteria
Inclusion Criteria:
Adult patients (> 30 years of age) at the time of the initial study visit.
Patients displaying a phenotype that consists of ≥ 100 nevi on the entire cutaneous surface and at least three large acquired nevi (LAN) > 5 mm in diameter. These patients have "atypical mole syndrome", which is a high-risk nevus phenotype and the target patient population in this study.
Patients with at least three clinically stable nevi between 5 and 20 mm in diameter.
Patients (or LAR) who are able to provide informed consent.
Patients with previous total body photography images taken at least 3 years prior
Exclusion Criteria:
Patients without at least three clinically stable nevi between 5 and 20 mm in diameter.
Patients with any electronic implantable devices.
Patients who are pregnant (verbally confirmed with the participant).
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 3 Locations for this study
Basking Ridge New Jersey, 07920, United States
Harrison New York, 10604, United States
New York New York, 10065, United States
How clear is this clinincal trial information?